David T Yeung

4.6k total citations · 1 hit paper
131 papers, 2.3k citations indexed

About

David T Yeung is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, David T Yeung has authored 131 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Hematology, 73 papers in Genetics and 45 papers in Public Health, Environmental and Occupational Health. Recurrent topics in David T Yeung's work include Chronic Myeloid Leukemia Treatments (80 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Acute Lymphoblastic Leukemia research (45 papers). David T Yeung is often cited by papers focused on Chronic Myeloid Leukemia Treatments (80 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Acute Lymphoblastic Leukemia research (45 papers). David T Yeung collaborates with scholars based in Australia, United States and New Zealand. David T Yeung's co-authors include Timothy P. Hughes, Deborah L. White, Susan Branford, David M. Ross, Andrew Grigg, John F. Seymour, Phuong Dang, Robin Filshie, Anthony P. Schwarer and Anthony K. Mills and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

David T Yeung

119 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

2013 508 citations David M. Ross, Susan Branford et al. Blood profile →

Peers

Countries citing papers authored by David T Yeung

Since Specialization

Citations

This map shows the geographic impact of David T Yeung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T Yeung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T Yeung more than expected).

Fields of papers citing papers by David T Yeung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T Yeung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T Yeung. The network helps show where David T Yeung may publish in the future.

Co-authorship network of co-authors of David T Yeung

This figure shows the co-authorship network connecting the top 25 collaborators of David T Yeung. A scholar is included among the top collaborators of David T Yeung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T Yeung. David T Yeung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine 2024 ·Blood ·(unknown), Nirmal Robinson, Monika Kutyna, Kelly Lim, (unknown), Steven Lane, David T Yeung, Agnes S. M. Yong, David M. Ross, Devendra Hiwase, Danièl Thomas	2
2	Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia 2024 ·Blood ·Thomas Wiseman, (unknown), (unknown), (unknown), (unknown), Deepak Singhal, David T Yeung, Hamish S. Scott, Christopher N Hahn, Danièl Thomas, Chung Hoow Kok, Devendra Hiwase	0
3	ANZTCT practice statement: sinusoidal obstruction syndrome/veno‐occlusive disease diagnosis and management 2024 ·Internal Medicine Journal ·Shaun Fleming, (unknown), John Coutsouvelis, Chris Fraser, Ashish Bajel, (unknown), Rachel Conyers, Ashley McEwan, David T Yeung, (unknown), Lochie Teague, (unknown), Edward S. Morris, Melissa Gabriel, (unknown), (unknown), (unknown), Nada Hamad	0
4	Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia 2024 ·Internal Medicine Journal ·Lynette Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony P. Schwarer, Jeff Szer, (unknown), Sonia Raj, (unknown), David T Yeung, Timothy P. Hughes, Naranie Shanmuganathan	2
5	Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine 2024 ·Blood ·Devendra Hiwase, David M. Ross, David T Yeung, Agnes S. M. Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy P. Hughes, John Reynolds, Danièl Thomas	2
6	CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib 2024 ·PubMed ·Chung Hoow Kok, Yazad Irani, Jade Clarson, Verity A Saunders, Phuong Dang, Naranie Shanmuganathan, Susan Branford, David T Yeung, Agnes S. M. Yong, Timothy P. Hughes	1
7	CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting 2024 ·PLoS ONE ·Kelly Lim, Winnie L. Kan, Pramod C. Nair, Monika Kutyna, Angel F. López, Timothy R. Hercus, David M. Ross, Steven Lane, Chun Yew Fong, Anna Brown, Agnes S. M. Yong, David T Yeung, Timothy P. Hughes, Devendra Hiwase, Danièl Thomas	0
8	Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol 2024 ·PubMed ·David T Yeung, Laura N Eadie, (unknown), Susan L. Heatley, Barbara J. McClure, (unknown), (unknown), Michael Osborn, Toby N. Trahair, Rosemary Sutton, Michelle J. Henderson, John Kwan, (unknown), Luciano Dalla‐Pozza, Kenneth F. Bradstock, Matthew Greenwood, Deborah L. White	1
9	Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib 2023 ·Blood Cancer Journal ·Chung Hoow Kok, Verity A Saunders, Phuong Dang, Naranie Shanmuganathan, Deborah L. White, Susan Branford, David T Yeung, Timothy P. Hughes	1
10	Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients 2023 ·Cancers ·(unknown), (unknown), Susan L. Heatley, Laura N Eadie, (unknown), (unknown), Barbara J. McClure, Rosemary Sutton, Luciano Dalla‐Pozza, Andrew S. Moore, Matthew Greenwood, Rishi S. Kotecha, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, James Breen, Deborah L. White	5
11	Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia 2023 ·Genes ·Laura N Eadie, (unknown), James Breen, Michael Osborn, (unknown), (unknown), Susan L. Heatley, Barbara J. McClure, David T Yeung, Tamás Révész, Ben Saxon, Deborah L. White	1
12	Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients 2023 ·Antimicrobial Agents and Chemotherapy ·(unknown), Aaron J. Heffernan, David T Yeung, Morgyn S. Warner, Sandra Peake, Uwe Hahn, Steven C. Wallis, Brett McWhinney, Jacobus Ungerer, Sepehr Shakib, Jason A. Roberts	3
13	Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia 2022 ·International Journal of Molecular Sciences ·Ville‐Petteri Mäkinen, (unknown), James Breen, David T Yeung, Deborah L. White	10
14	RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia 2022 ·Journal of Molecular Diagnostics ·Naranie Shanmuganathan, Carol Wadham, Daniel Thomson, Nur Hezrin Shahrin, (unknown), (unknown), Shalini Chaturvedi, Feng Yang, Jinghua Feng, Verity A Saunders, Chung Hoow Kok, David T Yeung, (unknown), (unknown), Ming Lin, Paul Wang, Hamish S. Scott, Timothy P. Hughes, Andreas Schreiber, Susan Branford	5
15	Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study 2021 ·Blood ·Shaun Fleming, John Reynolds, Ashish Bajel, Nicola C. Venn, John Kwan, John J. Moore, David T Yeung, (unknown), Michael F. Leahy, (unknown), Emma Verner, Leanne Berkahn, Rosemary Sutton, Andrew H. Wei, Matthew Greenwood	10
16	In-vitromodeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion geneRANBP2-ABL1- implications for targeted therapy 2021 ·Leukemia & lymphoma ·Susan L. Heatley, (unknown), (unknown), Tamara Leclercq, Barbara J. McClure, Laura N Eadie, Timothy P. Hughes, David T Yeung, Deborah L. White	3
17	Identification of a novel GOLGA4–JAK2 fusion gene in B‐cell acute lymphoblastic leukaemia 2021 ·British Journal of Haematology ·(unknown), (unknown), Susan L. Heatley, David T Yeung, Barbara J. McClure, Deborah L. White	4
18	B‐cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification 2021 ·British Journal of Haematology ·David T Yeung, Michael Osborn, Deborah L. White	17
19	Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells 2020 ·British Journal of Haematology ·Yazad Irani, Amy Hughes, Jade Clarson, Chung Hoow Kok, Naranie Shanmuganathan, Deborah L. White, David T Yeung, David M. Ross, Timothy P. Hughes, Agnes S. M. Yong	54
20	DUX Hunting—Clinical Features and Diagnostic Challenges Associated with DUX4-Rearranged Leukaemia 2020 ·Cancers ·(unknown), (unknown), Deborah L. White, David T Yeung	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact